+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bleeding Disorders Treatment Market by Product Type, Treatment Type, Route Of Administration, End Users, Distribution Channel, Disease Indication - Global Forecast to 2030- Product Image
Bleeding Disorders Treatment Market by Product Type, Treatment Type, Route Of Administration, End Users, Distribution Channel, Disease Indication - Global Forecast to 2030- Product Image
Sale

Bleeding Disorders Treatment Market by Product Type, Treatment Type, Route Of Administration, End Users, Distribution Channel, Disease Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010944
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bleeding Disorders Treatment Market grew from USD 14.80 billion in 2024 to USD 16.24 billion in 2025. It is expected to continue growing at a CAGR of 9.32%, reaching USD 25.28 billion by 2030.

Understanding the Evolving Landscape of Bleeding Disorders Treatment

The bleeding disorders treatment arena is experiencing rapid evolution driven by scientific breakthroughs, regulatory developments, and growing patient advocacy. Hemophilia A, Hemophilia B, and Von Willebrand Disease have long posed significant challenges in terms of morbidity and healthcare costs. Yet, recent advances in recombinant clotting factors, novel non-factor therapies, and precision medicine approaches are transforming care pathways.

This introduction sets the stage for a deeper exploration of how treatment paradigms are shifting from reactive, on‐demand interventions toward more proactive, prophylactic strategies. It underscores the importance of understanding not only the clinical innovations but also the market forces-ranging from tariff impacts to regional dynamics-that will shape access and adoption over the coming years. By weaving together insights from multiple data sources and expert perspectives, this section provides a foundation for appreciating the complex interplay between patient needs, technological progress, and market structure.

Transformative Shifts Redefining Treatment Paradigms

The bleeding disorders treatment paradigm has entered a phase of profound transformation. Gene therapy trials targeting Hemophilia A and B are demonstrating promising durability, while bispecific antibodies offer longer dosing intervals and improved patient convenience. Simultaneously, the emergence of digital health platforms and remote monitoring tools is enhancing adherence and real‐time intervention capabilities, shifting care beyond traditional clinical settings.

This shift is not limited to technological innovation. Payers and regulators are increasingly embracing value‐based reimbursement models to balance cost containment with patient outcomes. Collaboration between biopharmaceutical companies and patient advocacy groups is driving co‐creation of education programs and real‐world evidence studies, accelerating adoption of novel therapies. As a result, the market is transitioning from a volume‐based focus on factor usage toward an outcomes‐driven ecosystem where long‐term efficacy, safety, and quality of life take precedence. This transformation underscores the need for stakeholders to align around holistic care models that integrate therapeutic innovation, patient engagement, and economic sustainability.

Assessing the Ripple Effects of US Tariffs on Treatment Accessibility

United States tariffs slated for 2025 are poised to reverberate throughout the bleeding disorders treatment supply chain. Import duties on raw materials and biologic components used in the manufacture of clotting factors and synthetic analogs risk increasing production costs, which may be passed on to healthcare providers and, ultimately, patients. Manufacturers are evaluating strategic sourcing alternatives and may shift portions of their production footprint to mitigate tariff exposure.

The anticipated impact extends beyond cost pressures. Contract negotiations between biopharma companies and payers will likely incorporate tariff-related escalators, complicating formulary decisions. Smaller specialty suppliers may face heightened financial strain, potentially slowing the introduction of niche therapies. In response, industry players are advocating for tariff exemptions for critical medical imports and exploring vertical integration to secure key inputs. Navigating this complex policy environment will require agile supply chain management, proactive stakeholder engagement, and a clear understanding of how tariff dynamics intersect with broader market trends.

Unveiling Insights Across Market Segments

When examining the market through the lens of product type, anti-fibrinolytics, clotting factors and desmopressin each play distinct roles in therapeutic protocols, with recombinant clotting factors and plasma-derived variants catering to varying clinical needs. Transitioning to prophylactic treatment models has elevated demand for longer-acting formulations, while on-demand therapies remain critical for acute bleed management. The route of administration further differentiates patient experiences, as intravenous infusions continue to dominate severe case management, oral therapies gain traction for mild disorders, and subcutaneous options promise enhanced convenience for self-administration.

Looking at end users, the proliferation of home care settings reflects a broader trend toward decentralized treatment, with hospitals and specialty clinics maintaining pivotal roles in initial diagnosis and complex intervention. Distribution channels are evolving accordingly; e-commerce platforms are expanding patient access to specialty therapies, while hospital and retail pharmacies remain essential for legacy products and emergency interventions. Finally, analyzing disease indications reveals nuanced market dynamics: Hemophilia A represents the largest segment due to both prevalence and therapeutic innovation, whereas Hemophilia B and Von Willebrand Disease drive focused R&D efforts aimed at addressing unmet clinical needs. This multidimensional segmentation underscores the importance of tailored strategies that consider product attributes, treatment regimens, patient preferences, and distribution models simultaneously.

Regional Dynamics Shaping Market Evolution

Across the Americas, established healthcare infrastructures and robust reimbursement frameworks continue to support rapid uptake of advanced therapies, although cost containment pressures are driving demand for value propositions backed by real‐world evidence. In Europe, Middle East & Africa, heterogeneous regulatory environments and varying economic capacities create a patchwork of access, prompting manufacturers to pursue region-specific launch and pricing strategies. Collaborative initiatives between governments and industry are emerging to facilitate patient access in underserved markets.

Asia-Pacific markets are characterized by accelerating healthcare investment and growing prevalence awareness. China and Japan are leading in clinical trials and regulatory approvals for novel modalities, while Southeast Asian nations are strengthening distribution channels to improve reach. Regional trade agreements and local manufacturing partnerships are playing critical roles in reducing treatment costs and ensuring sustainable supply. These distinct regional dynamics highlight the need for nuanced market entry approaches and adaptive commercial models tailored to local healthcare ecosystems.

Leading Players Driving Innovation and Growth

Innovation leadership in this market is defined by companies that couple deep molecular insights with robust clinical development capabilities. Key players are advancing next-generation recombinant factors and gene therapies targeting long-term bleed prevention. Strategic acquisitions and licensing agreements are accelerating pipelines, while collaborations with biotechnology firms and academic institutions are broadening therapeutic portfolios. Investment in manufacturing capacity and quality assurance systems is enabling scalable production of complex biologics.

In parallel, several emerging biotech companies are carving out niches by focusing on non-factor therapies and novel delivery mechanisms. Their agility in early‐stage development is challenging established incumbents to optimize development timelines and cost structures. Ultimately, companies that excel in generating compelling clinical data, securing favorable regulatory pathways, and executing targeted commercialization plans will define the competitive landscape going forward.

Strategic Imperatives for Sustained Competitive Advantage

To maintain a competitive advantage, industry leaders should prioritize diversification of therapeutic platforms, investing in both recombinant and non-factor modalities that address a spectrum of bleeding disorders. Strengthening partnerships with contract manufacturing organizations and raw material suppliers will mitigate supply chain risks and tariff uncertainties. Integrating patient support programs and digital adherence tools into commercial strategies can enhance engagement and demonstrate real‐world value to payers.

Moreover, tailoring market access plans to regional dynamics is essential. Leveraging health economic and outcomes research to support value‐based pricing in mature markets, while adopting tiered pricing and collaborative access models in emerging economies, will optimize global reach. Finally, fostering closer collaboration with regulatory agencies and patient advocacy communities can accelerate approval processes and ensure that evolving therapies meet the needs of diverse patient populations. These strategic imperatives will enable stakeholders to navigate complexity and capture growth opportunities across the bleeding disorders treatment landscape.

Robust Methodology Ensuring Comprehensive Market Analysis

This analysis is grounded in a rigorous methodology combining primary and secondary research. Primary insights were gathered through in-depth interviews with clinicians, payers, patient advocates and industry executives. Secondary research encompassed a comprehensive review of peer-reviewed journals, regulatory filings and proprietary company materials. Quantitative data were triangulated to validate key findings and ensure consistency across sources.

The research also incorporated regional regulatory frameworks and tariff policies to assess their market implications. Disease epidemiology and treatment patterns were analyzed using real-world data sets, while segmentation studies provided granular insight into product, treatment, administration, end-user and distribution dynamics. This systematic approach guarantees a holistic view of the bleeding disorders treatment market, supporting robust decision-making for stakeholders.

Executive Perspective on Future Opportunities and Challenges

In summary, the bleeding disorders treatment market is at a pivotal juncture where scientific breakthroughs, policy shifts and evolving patient expectations intersect. The move toward preventative care, coupled with the promise of gene therapy and digital health integration, is reshaping treatment protocols and commercial strategies alike. Meanwhile, tariff dynamics and regional disparities necessitate agile responses and targeted access initiatives.

Moving forward, stakeholders who embrace data-driven decision-making, prioritize strategic partnerships and remain attuned to patient needs will be best positioned to thrive. By synthesizing innovation with pragmatic market planning, the industry can deliver more effective, accessible and sustainable solutions for those living with bleeding disorders. This executive summary lays the groundwork for deeper engagement with the full report’s insights and recommendations.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Anti Fibrinolytics
    • Clotting Factors
      • Plasma Derived
      • Recombinant
    • Desmopressin
  • Treatment Type
    • On Demand
    • Prophylactic
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • End Users
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • E Commerce
    • Hospital Pharmacy
    • Retail Pharmacy
  • Disease Indication
    • Hemophilia A
    • Hemophilia B
    • Von Willebrand Disease
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Bayer AG
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Sanofi S.A.
  • Swedish Orphan Biovitrum AB (publ)

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bleeding Disorders Treatment Market, by Product Type
8.1. Introduction
8.2. Anti Fibrinolytics
8.3. Clotting Factors
8.3.1. Plasma Derived
8.3.2. Recombinant
8.4. Desmopressin
9. Bleeding Disorders Treatment Market, by Treatment Type
9.1. Introduction
9.2. On Demand
9.3. Prophylactic
10. Bleeding Disorders Treatment Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Bleeding Disorders Treatment Market, by End Users
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Bleeding Disorders Treatment Market, by Distribution Channel
12.1. Introduction
12.2. E Commerce
12.3. Hospital Pharmacy
12.4. Retail Pharmacy
13. Bleeding Disorders Treatment Market, by Disease Indication
13.1. Introduction
13.2. Hemophilia A
13.3. Hemophilia B
13.4. Von Willebrand Disease
14. Americas Bleeding Disorders Treatment Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Bleeding Disorders Treatment Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Bleeding Disorders Treatment Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. CSL Limited
17.3.2. Grifols, S.A.
17.3.3. Takeda Pharmaceutical Company Limited
17.3.4. Octapharma AG
17.3.5. Bayer AG
17.3.6. Novo Nordisk A/S
17.3.7. F. Hoffmann-La Roche Ltd
17.3.8. Pfizer Inc.
17.3.9. Sanofi S.A.
17.3.10. Swedish Orphan Biovitrum AB (publ)
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BLEEDING DISORDERS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. BLEEDING DISORDERS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. BLEEDING DISORDERS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLEEDING DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ANTI FIBRINOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 50. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 53. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 57. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 91. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 93. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 96. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 98. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 100. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 103. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 112. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 114. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 117. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 119. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 121. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 124. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 147. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 149. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 152. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 161. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 163. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 166. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 189. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 191. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 194. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 196. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 198. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 201. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 217. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 219. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 222. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 241. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 244. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 246. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 248. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 251. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 253. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 258. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 281. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 282. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 283. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 284. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 286. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MIL

Companies Mentioned

The companies profiled in this Bleeding Disorders Treatment market report include:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Bayer AG
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Sanofi S.A.
  • Swedish Orphan Biovitrum AB (publ)

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 16.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 25.28 Billion
Compound Annual Growth Rate9.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Bleeding Disorder Diagnostics Market by Product Type, Technology, End User, Application, Disease Type - Global Forecast to 2030 - Product Image

Bleeding Disorder Diagnostics Market by Product Type, Technology, End User, Application, Disease Type - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Bleeding Disorders Treatment - Global Strategic Business Report - Product Image

Bleeding Disorders Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Bleeding Disorders Treatment Market Report 2025 - Product Image

Bleeding Disorders Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Bleeding Disorders Testing Market: Global Opportunity Analysis and Industry Forecast, 2024-2033 - Product Image

Bleeding Disorders Testing Market: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • Report
  • 260 Pages
  • Global
From
Bleeding Disorder Testing Market Report 2025 - Product Image

Bleeding Disorder Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.